KFA
CRVS icon

Kelleher Financial Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Kelleher Financial Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75
Closed -$578 – 690
2025
Q4 		$578 Hold
75
– – ﹤0.01% 681
2025
Q3 		$553 Buy
+75
New +$384 ﹤0.01% 622

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Kelleher Financial Advisors's CRVS Position: Q1 2026 in Review

Kelleher Financial Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 75 shares — an estimated $578 sold.

Kelleher Financial Advisors first reported a position in CRVS in Q3 2025 and held it in 2 quarters. The position peaked at $578 in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Kelleher Financial Advisors reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Kelleher Financial Advisors sold 75 Corvus Pharmaceuticals shares in Q1 2026, an estimated $578.
  • Kelleher Financial Advisors first reported a position in Corvus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Kelleher Financial Advisors's Corvus Pharmaceuticals position peaked at $578 in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Kelleher Financial Advisors's 13F filing for Q1 2026, filed 8 May 2026.